Revolution MedicinesRVMD
RVMD
About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Employees: 490
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
116% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 56
100% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 30
21% more funds holding in top 10
Funds holding in top 10: 19 [Q3] → 23 (+4) [Q4]
9% more funds holding
Funds holding: 251 [Q3] → 273 (+22) [Q4]
7% more capital invested
Capital invested by funds: $7.85B [Q3] → $8.4B (+$552M) [Q4]
1.71% more ownership
Funds ownership: 103.6% [Q3] → 105.31% (+1.71%) [Q4]
16% less call options, than puts
Call options by funds: $42.3M | Put options by funds: $50.2M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$62
50%
upside
Avg. target
$72
73%
upside
High target
$87
110%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
UBS Eliana Merle 35% 1-year accuracy 8 / 23 met price target | 72%upside $71 | Buy Maintained | 8 Jan 2025 |
Wedbush Robert Driscoll 15% 1-year accuracy 9 / 59 met price target | 62%upside $67 | Outperform Maintained | 6 Dec 2024 |
Needham Ami Fadia 44% 1-year accuracy 73 / 167 met price target | 50%upside $62 | Buy Maintained | 6 Dec 2024 |
HC Wainwright & Co. Robert Burns 27% 1-year accuracy 44 / 166 met price target | 74%upside $72 | Buy Maintained | 4 Dec 2024 |
Guggenheim Michael Schmidt 30% 1-year accuracy 8 / 27 met price target | 110%upside $87 | Buy Maintained | 3 Dec 2024 |
Financial journalist opinion
Based on 3 articles about RVMD published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.
Positive
Zacks Investment Research
1 week ago
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
3 weeks ago
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET.
Negative
Zacks Investment Research
1 month ago
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
1 month ago
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 43r d Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT.
Positive
24/7 Wall Street
2 months ago
Insiders Are Loving These 6 Stocks Right Now
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.
Neutral
GlobeNewsWire
2 months ago
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million
Neutral
Seeking Alpha
2 months ago
Revolution Medicines: Risky Buy On Recent Share Price Dip
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDAC, with potential expansion into NSCLC and CRC, positioning it as a potential new standard of care. Despite a recent stock dip due to a $600m public offering, Revolution's robust cash position and promising pipeline offer significant long-term potential.
Positive
Benzinga
2 months ago
Top 3 Health Care Stocks That Could Blast Off In December
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
2 months ago
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are to be sold by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,445,652 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $750.0 million before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares and excluding the exercise of any pre-funded warrants. The offering is expected to close on December 5, 2024, subject to customary closing conditions.
Charts implemented using Lightweight Charts™